SNGX (Soligenix) Float Percentage Of Total Shares Outstanding : 79.39% (As of Apr. 13, 2025)

View and export this data going back to 1994. Start your Free Trial

What is Soligenix Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Soligenix's float shares is 2.51 Mil. Soligenix's total shares outstanding is 3.16 Mil. Soligenix's float percentage of total shares outstanding is 79.39%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Soligenix's Insider Ownership is 63.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Soligenix's Institutional Ownership is 1.22%.

Soligenix Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Soligenix's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	2.51	/	3.16
	=	79.39%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Soligenix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

0A6I:UK

Address

29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website

https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Executives

Timothy R. Cote	director	3529 TILDEN STREET, NW, WASHINGTON DC 20008
Richard Straube	officer: CMO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Christopher Schaber	director, officer: Chairman, CEO and President	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Jonathan L. Guarino	officer: Chief Financial Officer	100 WELLESLEY WAY, FREEHOLD NJ 07728
Oreola Donini	officer: CSO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Robert J. Rubin	director	7901 SPRINGER ROAD, BETHESDA MD 20817
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Mark E. Pearson	director, 10 percent owner	3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128
Preta Martina Cavazza	other: Former 10% Owner	VIA SUDAFRICA 20, ROME L6 00144
Enrico Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Francesca Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144